CT-996
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
Carmot Australia First Pty Ltd · Phase 1 · Completed · Enrollment 94
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part 1: CT-996 SAD Cohort 1 | n/r | n/r | n/r | n/r |
| Part 1: CT-996 SAD Cohort 2 | n/r | n/r | n/r | n/r |
| Part 1: CT-996 SAD Cohort 3, Then SAD Cohort 5 | n/r | n/r | n/r | n/r |
| Part 1: CT-996 SAD Cohort 4 | n/r | n/r | n/r | n/r |
| Part 1: CT-996 SAD Cohort 6 | n/r | n/r | n/r | n/r |
| Part 1: Placebo SAD Cohort | n/r | n/r | n/r | n/r |
| Part 2: CT-996 MAD Cohort 1 | n/r | n/r | n/r | n/r |
| Part 2: CT-996 MAD Cohort 2 | n/r | n/r | n/r | n/r |
| Part 2: CT-996 MAD Cohort 3 | n/r | n/r | n/r | n/r |
| Part 2: Placebo MAD Cohort | n/r | n/r | n/r | n/r |
| Part 3: CT-996 MD T2DM Cohort 1 | n/r | n/r | n/r | n/r |
| Part 3: CT-996 MD T2DM Cohort 2 | n/r | n/r | n/r | n/r |
| Part 3: Placebo MD T2DM Cohort | n/r | n/r | n/r | n/r |
Not shown
- Part 1: CT-996 SAD Cohort 1: endpoint not reported
- Part 1: CT-996 SAD Cohort 2: endpoint not reported
- Part 1: CT-996 SAD Cohort 3, Then SAD Cohort 5: endpoint not reported
- Part 1: CT-996 SAD Cohort 4: endpoint not reported
- Part 1: CT-996 SAD Cohort 6: endpoint not reported
- Part 1: Placebo SAD Cohort: endpoint not reported
- Part 2: CT-996 MAD Cohort 1: endpoint not reported
- Part 2: CT-996 MAD Cohort 2: endpoint not reported
- Part 2: CT-996 MAD Cohort 3: endpoint not reported
- Part 2: Placebo MAD Cohort: endpoint not reported
- Part 3: CT-996 MD T2DM Cohort 1: endpoint not reported
- Part 3: CT-996 MD T2DM Cohort 2: endpoint not reported
- Part 3: Placebo MD T2DM Cohort: endpoint not reported